Avila Therapeutics Completes Dosing of First Patient Cohort in Phase 1b Clinical Study of AVL-292, a Selective Bruton's Tyrosine Kinase Inhibitor for the Treatment of B Cell Cancers
9/14/2011 9:04:09 AM
BEDFORD, Mass.--(BUSINESS WIRE)--Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has completed 28 days of dosing of the first cohort of patients in its Phase 1b clinical trial of AVL-292 and is now advancing to the second dose cohort in this trial. The trial is being conducted in patients with B cell cancer malignancies including B-cell Non-Hodgkin Lymphoma (B-NHL) and Chronic Lymphocytic Leukemia (CLL). AVL-292 is a novel, orally available, and highly selective covalent inhibitor that inhibits Bruton’s tyrosine kinase (Btk). In two completed Phase 1a studies in healthy volunteers, AVL-292 demonstrated a favorable safety, tolerability, and pharmacokinetic profile.